Hussman Strategic Advisors Inc. Purchases New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Hussman Strategic Advisors Inc. bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 31,500 shares of the specialty pharmaceutical company's stock, valued at approximately $1,741,000. Hussman Strategic Advisors Inc. owned approximately 0.15% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of ANIP. Thrivent Financial for Lutherans raised its position in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after purchasing an additional 299 shares during the period. Louisiana State Employees Retirement System increased its stake in ANI Pharmaceuticals by 3.9% during the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company's stock valued at $477,000 after purchasing an additional 300 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in ANI Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after purchasing an additional 310 shares in the last quarter. New York State Teachers Retirement System raised its holdings in ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company's stock worth $1,439,000 after buying an additional 394 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after buying an additional 412 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded down $1.73 during trading on Friday, reaching $57.94. The company's stock had a trading volume of 218,474 shares, compared to its average volume of 182,655. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.81. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -105.35 and a beta of 0.74. The firm has a 50 day moving average of $57.08 and a 200-day moving average of $58.23. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ANIP shares. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 target price for the company. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, StockNews.com raised ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 5th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $77.71.

Insider Buying and Selling

In related news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Nikhil Lalwani sold 33,481 shares of the firm's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares of the company's stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,781 shares of company stock worth $2,465,372. Insiders own 12.70% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.